RELMADA THERAPEUTICS, INC.: 10-Q filed 2017-11-14
What RELMADA THERAPEUTICS, INC. reported in its quarterly report filed 2017-11-14 (fiscal Q1 2017): 23 published measures, 49 facts as tagged in accession 0001213900-17-012121.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2017-11-14
- Fiscal period
- fiscal Q1 2017
- Accession
- 0001213900-17-012121 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All RELMADA THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 5,613,561 | USD | |
| At 2017-06-30 | 2,836,923 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 4,148,899 | USD | |
| At 2017-06-30 | 1,376,639 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 1,464,662 | USD | |
| At 2017-06-30 | 1,460,284 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 4,684,567 | USD | |
| At 2017-06-30 | 1,710,512 | USD | |
| At 2016-09-30 | 6,221,659 | USD | |
| At 2016-06-30 | 8,500,207 | USD | |
| At 2015-06-30 | 22,469,960 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | -981,686 | USD | 92 |
| 2016-07-01 to 2016-09-30 | -1,640,581 | USD | 92 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | -86,365,141 | USD | |
| At 2017-06-30 | -85,383,455 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 4,358 | USD | |
| At 2017-06-30 | 2,315 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 68,870 | USD | 92 |
| 2016-07-01 to 2016-09-30 | 172,064 | USD | 92 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | -980,856 | USD | 92 |
| 2016-07-01 to 2016-09-30 | -1,616,596 | USD | 92 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 5,265,132 | USD | |
| At 2017-06-30 | 2,474,917 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 3,470,024 | USD | |
| At 2017-06-30 | 1,376,639 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 350,542 | USD | |
| At 2017-06-30 | 529,558 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 980,856 | USD | 92 |
| 2016-07-01 to 2016-09-30 | 1,616,596 | USD | 92 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 165,750 | USD | 92 |
| 2016-07-01 to 2016-09-30 | 364,152 | USD | 92 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 12,545,120 | shares | |
| At 2017-06-30 | 12,528,374 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 87,817,258 | USD | |
| At 2017-06-30 | 86,831,211 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 2,500 | USD | |
| At 2017-06-30 | 2,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 21,961 | USD | |
| At 2017-06-30 | 21,961 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 407,307 | USD | |
| At 2017-06-30 | 394,558 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 815,106 | USD | 92 |
| 2016-07-01 to 2016-09-30 | 1,252,444 | USD | 92 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 548 | USD | 92 |
| 2016-07-01 to 2016-09-30 | 20,163 | USD | 92 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | -830 | USD | 92 |
| 2016-07-01 to 2016-09-30 | -23,985 | USD | 92 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | -232,510 | USD | 92 |
| 2016-07-01 to 2016-09-30 | -587,992 | USD | 92 |
Inspect the source
- Entity
- RELMADA THERAPEUTICS, INC. / CIK 0001553643
- Captured
- 2026-09-19T11:18:56.464Z
- SEC response SHA-256
34acb6579adb694402af1f940d83014f7841c8cf763b03e27ee64d386466bb53
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001553643.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))